ArticleMedicine2026
Study on the mechanism of action of Chaihu Guizhi Ganjiang Decoction for the treatment of slow transit constipation combined with depression based on network pharmacology and molecular docking.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Based on network pharmacology and molecular docking technology, this study investigated the mechanism of action of Chaihu Guizhi Ganjiang Decoction (CGGD) in the treatment of slow transit constipation (STC) combined with depression. The Traditional Chinese Medicine System Pharmacology Database Analysis Platform and BATMAN-TCM databases were utilized to screen the active ingredients and target proteins of CGGD. The keywords "slow transit constipation" and "depression" were used to query the GEO, GeneCards, and OMIM databases to obtain the disease targets; the intersection targets of the TCM formula and the disease were taken to analyze the protein interactions among the target genes, and to construct the protein-protein interaction network diagram and the "drug-ingredient-target-disease" interaction network. Gene Ontology functional enrichment and Kyoto Encyclopedia of Genes and Genomes pathway were used to analyze the enrichment, and molecular docking was used to further confirm the interactions between core ingredients and key targets. Identified 138 active ingredients, 141 target proteins, and 17,110 disease targets. Analysis yielded 10 core ingredients, including quercetin, kaempferol, wogonin, and baicalein, alongside 10 key targets such as estrogen receptor 1, epidermal growth factor receptor, caspase-3, and B-cell lymphoma-2. Molecular docking studies demonstrated strong binding affinities between core ingredients and key targets. Enrichment analysis identified 440 biological processes and 131 pathways. CGGD primarily intervenes in STC combined with depression through pathways including the phosphatidylinositol 3-kinase-Akt signaling pathway, the mitogen-activated protein kinase signaling pathway, and the apoptosis pathway. Through an integrated network pharmacology approach, this study describes the synergistic effects of multiple ingredients, targets, and pathways of CGGD in the treatment of STC combined with depression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.